Press Releases

Date Title and Summary Additional Formats
Toggle Summary Theravance to Present at the JP Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., January 7, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's chief executive officer, is scheduled to present at the 23rd Annual JP Morgan Healthcare Conference on Monday, January 10, 2005 at 1:30 p.m. PT (4:30 p.m. ET).
View HTML
Toggle Summary Theravance Announces Initiation of Phase 1 Clinical Study with Investigational Medicine for Gastrointestinal Motility Dysfunction
Theravance Announces Initiation of Phase 1 Clinical Study with Investigational Medicine for Gastrointestinal Motility Dysfunction South San Francisco, CA, January 3, 2005 - Theravance, Inc. (NASDAQ: THRX) announced today that it has enrolled the first subjects in a Phase 1 clinical study designed
View HTML
Toggle Summary Theravance Announces Results From FAST 2 - A Phase 2 Clinical Study With Investigational Antibiotic Telavancin
Phase 3 Clinical Program Underway for Serious Infections Caused by Gram-positive Bacteria
View HTML
Toggle Summary Theravance, Inc. Reports Third Quarter 2004 Financial Results
Initiated Telavancin Phase 3 Clinical Studies Completed Initial Public Offering
View HTML
Toggle Summary Theravance Announces Results From Pre-clinical And Clinical Studies With Investigational Antibiotic Telavancin
Rapid Bactericidal Activity, Multiple Mechanisms and Clinical Activity Observed Phase 3 Clinical Study Underway for Complicated Infections Caused by Gram-positive Bacteria
View HTML
Toggle Summary Theravance To Report Third Quarter 2004 Financial Results November 3, 2004
Theravance To Report Third Quarter 2004 Financial Results November 3, 2004 SOUTH SAN FRANCISCO, CA / October 19, 2004 - Theravance, Inc. (Nasdaq: THRX) announced today that it will release financial results for the period ended September 30, 2004 after market close on Wednesday, November 3, 2004
View HTML
Toggle Summary Theravance And GlaxoSmithKline Consummate Strategic Alliance
SOUTH SAN FRANCISCO, CA / May 11, 2004 -- Theravance, Inc., a privately-held pharmaceutical company, announced today that the strategic alliance with GlaxoSmithKline (GSK), previously announced on March 31st, was consummated and funded after receiving the requisite regulatory and Theravance
View HTML
Toggle Summary Theravance Announces Promising Results From Research And Clinical Studies With Investigational Antibiotic Telavancin
Rapid Bactericidal Activity and Efficacy Demonstrated in MRSA Pneumonia Model Phase 2 Trials Underway for Serious Infections Caused by Gram-Positive Bacteria
View HTML
Toggle Summary GlaxoSmithKline and Theravance to form Strategic Alliance
LONDON, UK and SOUTH SAN FRANCISCO, CA / March 31, 2004 -- GlaxoSmithKline plc (GSK) and Theravance, Inc., a privately-held pharmaceutical company, announced today that they have entered into an innovative broad-based strategic alliance to develop and commercialize novel medicines across a variety
View HTML
Toggle Summary Theravance Announces Positive Phase 2 Results for Once-Daily Beta2-Agonists in Development for Asthma and COPD
Theravance Announces Positive Phase 2 Results for Once-Daily Beta2-Agonists in Development for Asthma and COPD SOUTH SAN FRANCISCO, CA December 3, 2003/ PR Newswire/ -- Theravance, Inc. announced today that the lead compounds in its alliance with GlaxoSmithKline (GSK) to identify new long-acting,
View HTML

Copyright West LLC. Minimum 15 minutes delayed.

Contact

Toll-Free
877-202-1097

Innoviva Investor Relations & Media
Sloane and Company
212-446-9500

For business development inquiries,
please contact investor.relations@inva.com.